Nice to have another #COVID therapeutic that appears to have robust clinical efficacy and safety with $LLY's JAK inhibitor Olumiant, in addition to Remdesivir and dexamethasone. Does Olumiant's data in combo with Remdesivir, bode well for $CTI's #Pacritinib PRE-VENT monotherapy study?
How does the dose of #Pacritinib being used in the PRE-VENT trial compare to the dose in myelofibrosis? If the dosing in MF is the same as in COVID then the safety data in MF must have been pretty good since they submitted for approval.
Is interim data coming soon?
See our AmpCard to learn more about CTIC & Pacritinib.